I admit this is at best a very rough analogy. But we have no manufacturing process patent cases to guide us (at least that I know of), so the formulation cases are the best we have.
The point of the analogy is mostly that, unlike COM patents, with process/formulation patents there are potentially ways to design around the patent. My single-digit projection is based on a combination of the the "design-around" issue and the uncertainty of the applicability of the FDA exemption to this case.
Market Data 
Markets 
AI
